Evidence map›Paper›PMID 10944597›Full record

Trial reportBritish journal of cancer2000

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.

W K Yung, R E Albright, J Olson, R Fredericks, K Fink, M D Prados, M Brada, A Spence, R J Hohl, W Shapiro and 12 more

Open access · hybridAbstract readClinical TrialClinical Trial, Phase IIComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 334 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
334citing papers in PubMed, 15 pooled it
24.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

334 citing papers in PubMed, 15 syntheses or guidelines pooled it, 935 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.The Cochrane database of systematic reviews · 2017
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Economics of Malignant Gliomas: A Critical Review.Journal of oncology practice · 2015
    Pooled it
  11. Guideline
  12. Guideline
  13. Pooled it
  14. Temozolomide for high grade glioma.The Cochrane database of systematic reviews · 2013
    Pooled it
  15. Pooled it
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

274 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 19 institutions in 4 countries.

W K YungDepartment of Neuro-Oncology, UTMD Anderson Cancer Center, Box 100, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA.
R E Albright
J Olson
R Fredericks
K Fink
M D Prados
M Brada
A Spence
R J Hohl
W Shapiro
M Glantz
H Greenberg
R G Selker
N A Vick
R Rampling
H Friedman
P Phillips
J Bruner
N Yue
D Osoba
S Zaknoen
V A Levin
The University of Texas MD Anderson Cancer Center · USBarrow Neurological Institute · USBC Cancer Agency · CACenter for Neuro-Oncology · USDuke University · USEmory University · USInstitute of Cancer Research · GBMemorial Hospital of Rhode Island · USMerck (Japan) · JPNorthShore University HealthSystem · USSt. Joseph Medical Center · USThe University of Texas Southwestern Medical Center · USUniversity of California, San Francisco · USUniversity of Iowa Hospitals and Clinics · USUniversity of Michigan · USUniversity of Mississippi · USUniversity of Pennsylvania · USUniversity of Washington · USWestern Infirmary · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m(2)/day or 150 mg/m(2)/day (prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m(2)/day or 125 mg/m(2)/day (prior chemotherapy) for 28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [+3]) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ was 21%, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8% (P = 0.008, for the comparison). Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (P = 0.0063). The 6-month overall survival rate for TMZ patients was 60% vs. 44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity.

Indexed as

AdultAgedAntineoplastic AgentsAntineoplastic Agents, AlkylatingBrain NeoplasmsDacarbazineDisease-Free SurvivalFemaleGlioblastomaGliosarcomaHumansMaleMiddle AgedProcarbazinePrognosisQuality of LifeAntineoplastic AgentsAntineoplastic Agents, AlkylatingDacarbazineProcarbazineTemozolomide

Identifiers

PMID10944597
PMCPMC2363506
OpenAlexW1977392502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.